血清CA125、HE4水平与子宫内膜癌患者淋巴结转移的相关性

betway必威登陆网址（betway.com ）学报››2021,Vol. 42››Issue (3): 207-209.DOI:10.3969/j.issn.1004-7115.2021.03.011

血清CA125、HE4水平与子宫内膜癌患者淋巴结转移的相关性

翟素平¹, 孙晖², 马昕炜³

南阳市中心医院 1.医学检验科,
2.妇一科,
3.科教科,河南南阳 473009

收稿日期:2020-11-08出版日期:2021-03-25发布日期:2021-09-01
作者简介:翟素平,本科,副主任技师,主要从事临床检验工作,E-mail:mox3we@163.com。

Correlation between serum CA125, HE4 levels and lymph node metastasis in patients with endometrial carcinoma

ZHAI Su-ping¹, SUN Hui², MA Xin-wei³

1. Dept. of Medical Laboratory Science,
2. Dept. of Gynecology,
3. Dept. of Science and Education, Nanyang Central Hospital, Nanyang 473009, China

Received:2020-11-08Online:2021-03-25Published:2021-09-01

摘要/Abstract

摘要：目的探讨血清糖类抗原125(CA125)、人附睾蛋白4(HE4)水平与子宫内膜癌患者淋巴结转移的相关性。方法选择2018年7月—2020年2月于我院接受治疗的68例子宫内膜癌患者为研究对象,所有入选者均行MRI检查淋巴结转移情况,并接受血清CA125、HE4水平检测,分析血清CA125、HE4水平与子宫内膜癌患者淋巴结转移的相关性。结果经MRI检查结果显示,68例子宫内膜癌患者发生淋巴结转移9例,占13.24%;未发生淋巴结转移59例,占86.76%;子宫内膜癌患者淋巴结转移与年龄、体重指数、子宫内膜厚度、绝经情况无关,差异无统计学意义(P＞0.05);子宫内膜癌患者淋巴结转移与血清CA125、HE4水平有关,差异有统计学意义(P＜0.05);经Logistic回归分析结果显示,血清CA125、HE4水平升高是导致子宫内膜癌患者发生淋巴结转移的危险因素(OR＞1,P＜0.05);绘制ROC曲线,结果显示,血清CA125、HE4水平预测子宫内膜癌患者发生淋巴结转移的AUC分别为0.825、0.835,均具有一定预测价值。结论血清CA125、HE4水平与子宫内膜癌患者淋巴结转移情况密切相关,其水平升高是患者发生淋巴结转移的重要影响因素,临床可通过监测患者血清CA125、HE4水平,对患者淋巴结转移的预防及治疗提供可靠依据。

关键词:子宫内膜癌,糖类抗原125,人附睾蛋白4,淋巴结转移

Abstract:Objective: To investigate the correlation between serum carbohydrate antigen 125 (CA125), human epididymal protein 4 (HE4) levels and lymph node metastasis in patients with endometrial carcinoma. Methods: Sixty-eight patients with endometrial carcinoma in our hospital from February 2018 to July 2020 were retrospectively analyzed, all patients underwent MRI examination, the condition of lymph node metastasis was measured, their serum CA125 and HE4 levels were detected, and the correlation between serum CA125, HE4 levels and lymph node metastasis in patients with endometrial carcinoma was analyzed. Results: The result of MRI examination showed that, among 68 cases of patients with endometrial carcinoma, lymph node metastasis occurred in 9 cases, accounting for 13.24%; lymph node metastasis didn't occur in 59 cases, accounting for 86.76%; lymph node metastasis in patients with endometrial carcinoma was not associated with age, body mass index, endometrial thickness and menopause, and the difference was not significant statistically (P>0.05); the levels of CA125 and HE4 were correlated with lymph node metastasis in patients with endometrial carcinoma, and the difference was significant statistically(P<0.05); the results of Logistic regression analysis showed that increasing serum CA125 and HE4 levels were risk factors for lymph node metastasis in patients with endometrial carcinoma(OR>1, P<0.05); the ROC curve was drawn, and the results showed that serum CA125 and HE4 levels predicted the AUC of lymph node metastasis in patients with endometrial carcinoma were 0.825 and 0.835 respectively, which had certain predictive value. Conclusion: Serum CA125 and HE4 levels are closely related to lymph node metastasis in patients with endometrial carcinoma, the increase of their levels is an important factor in the occurrence of lymph node metastasis in patients with this disease, serum CA125 and HE4 levels can be monitored clinically to provide a reliable basis for the prevention and treatment of lymph node metastasis in patients with this disease.

Key words:endometrial carcinoma,carbohydrate antigen 125,human epididymal protein 4,lymph node metastasis

中图分类号:

R737.3

翟素平, 孙晖, 马昕炜. 血清CA125、HE4水平与子宫内膜癌患者淋巴结转移的相关性[J]. betway必威登陆网址（betway.com ）学报, 2021, 42(3): 207-209.

ZHAI Su-ping, SUN Hui, MA Xin-wei. Correlation between serum CA125, HE4 levels and lymph node metastasis in patients with endometrial carcinoma[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2021, 42(3): 207-209.

参考文献

[1] 罗丹,冯绣梅.子宫内膜癌治疗的研究进展[J].医学综述,2020,26(8):1542-1546.
[2] 包媛媛,洛若愚.子宫内膜癌早期筛查与诊断研究进展[J].医学综述,2020,26(1):76-80+85.
[3] 程峰,陈鑫,杨悦.子宫内膜癌患者腹主动脉旁淋巴结切除研究进展[J].中国基层医药,2020,27(1):126-128.
[4] 李状.子宫内膜癌淋巴结转移的评估与处理的现状[J].国际妇产科学杂志,2018,45(5):500-503.
[5] 子宫内膜癌筛查专家委员会.子宫内膜癌筛查和早期诊断专家共识(草案)[J].中国实用妇科与产科杂志,2017,33(10):1050-1052.
[6] 王婧元,戴一博.子宫内膜透明细胞癌的治疗进展[J].实用妇产科杂志,2019,35(12):902-905.
[7] 李秋霞,余贵媛.年轻子宫内膜癌女性保留生育及卵巢功能的治疗进展[J].国际妇产科学杂志,2018,45(1):75-79.
[8] 于靓,王劲红,付小萌,等.前哨淋巴结检测在子宫内膜癌精准治疗中的技术研究[J].中国计划生育和妇产科,2020,12(1):69-72.
[9] 蒋丽娜,李嘉舟,孟青.超声、CT及MRI对子宫内膜癌分期、粘膜层侵犯及淋巴转移的判断价值比较[J].中国CT和MRI杂志,2017,15(3):100-102,127.
[10] 张湛,许相丰,魏刚.MRI在宫颈癌分期及淋巴结转移评估中的价值探讨[J].天津医药,2016,44(8):1022-1025.
[11] 刘睿倩.乳腺癌基因-1和CA125在子宫内膜癌患者中的表达及意义[J].中华全科医学,2017,15(1):88-91.
[12] 侯英,张蒙,耿宇宁.血清CA125、CA199联合脂联素对子宫内膜癌的诊断价值[J].实用癌症杂志,2019,34(11):1760-1763.
[13] 孟波,文晓燕,宋芳.子宫内膜癌组织中BRCA1、CA125的表达及其意义[J].中国妇幼保健,2018,33(9):2096-2099.
[14] 霍宇倩,段萍.CA125联合HE4检测对子宫内膜癌的诊断价值[J].中国妇幼保健,2019,34(19):4435-4437.
[15] 黎阳成,朱雪莲,贺志军.子宫内膜癌患者HE4、CA125水平变化及其临床意义[J].检验医学与临床,2019,16(4):474-477+481.